Shockwave Medical

New Capabilities

Incumbent coronary lithotripsy supplier

Abbott's SonicForce met both of its primary endpoints in a 335-patient U.S. study of severely calcified coronary arteries. Thirty-day target lesion failure was 0.3% and procedural success was 97.0%, results presented Nov. 1 at the TCT conference in San Diego and published in JACC: Cardiovascular Interventions.

Updated 4 days ago